NOVEL PLASMA PROTEINS:
SCIENTIFIC AND COMMERCIALIZATION POTENTIAL
IN THE UNITED STATES

2013

Throughout the plasma industry’s history, novel plasma proteins have been commercialized, increasing the therapeutic value of human plasma, and spreading the manufacturing cost of the finished products. New proteins introduced on the U.S. market in the recent past include Factor XI, Protein C, Fibrinogen and C-1 esterase inhibitor.

Even though hundreds of proteins can be found in human plasma, only a few have been commercialized to date. Most of those proteins which have not yet been commercialized are present in very low concentrations in plasma, but some exist in sufficient quantities to warrant their extraction and purification.

The Marketing Research Bureau’s report analyzes the following proteins.

  • Ceruloplasmin
  • Factor II
  • Factor V
  • Factor X
  • Factor XII
  • Haptoglobin
  • Hemopexin
  • High Density Lipoproteins (Apolipoprotein A-I, A-II)
  • Plasmin
  • Plasminogen
  • Alpha 1-Microglobulin
  • Alpha 2-Macroglobulin
  • Transferrin

A scientific rationale, manufacturing yield and market potential is provided for each of the fractions. Prevalence and incidence, as well as information about the current development status of each protein are included.

A detailed proposal is available from the Marketing Research Bureau.